Safety and Tolerability of a Rapidly Escalating Dose-Loading Regimen for Risperidone
J Clin Psychiatry 2000;61(12):909-911
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
This article was retracted. Please see the notice of retraction.
Background: Risperidone is an
"atypical" antipsychotic with strong binding affinity
for dopamine-2 and serotonin-2 receptors. Risperidone is often
used to treat hospitalized patients who have acute psychotic
decompensation, and the therapeutic target dose commonly used is
2 to 6 mg/day. The most common clinical practice is to titrate
the dose of risperidone to the target therapeutic dose over
several days. This study investigated the safety and tolerability
of a rapid oral-loading regimen for risperidone developed to
achieve therapeutic doses of this antipsychotic within 24 hours.
Method: Rapid-loaded risperidone was initiated
with 1 mg. Subsequent doses were increased by 1 mg every 6 to 8
hours up to 3 mg. Dose increases were contingent on tolerance of
last administered dose.
Results: Of a sample of 11 consecutive
inpatients admitted to an acute psychiatric facility who were
treated with this protocol, 7 tolerated the most rapid titration,
achieving a standing dose of 3 mg b.i.d. in 16 hours. Three
required a slightly slower titration and achieved this target
dose in 24 hours. One patient could not tolerate the 3-mg dose
but tolerated a standing regimen of 2 mg t.i.d. No patient
experienced serious extrapyramidal side effects, sedation, or any
other adverse event during the rapid titration, and in no case
did risperidone have to be discontinued.
Conclusion: These results suggest that
aggressive dosing of risperidone is well tolerated in most